News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
588,733 Results
Type
Article (47268)
Company Profile (122)
Press Release (541332)
Multimedia
Podcasts (146)
Webinars (19)
Section
Business (156066)
Career Advice (2430)
Deals (29202)
Drug Delivery (142)
Drug Development (71754)
Employer Resources (158)
FDA (16157)
Job Trends (12564)
News (280528)
Policy (30787)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2387)
Academic (1)
Accelerated approval (37)
Adcomms (36)
Allergies (140)
Alliances (37135)
ALS (168)
Alzheimer's disease (1745)
Antibody-drug conjugate (ADC) (328)
Approvals (16307)
Artificial intelligence (509)
Autoimmune disease (168)
Automation (36)
Bankruptcy (319)
Best Places to Work (9659)
BIOSECURE Act (23)
Biosimilars (195)
Biotechnology (71)
Bladder cancer (161)
Brain cancer (55)
Breast cancer (607)
Cancer (4687)
Cardiovascular disease (424)
Career advice (2054)
Career pathing (39)
CAR-T (263)
CDC (63)
Celiac Disease (1)
Cell therapy (739)
Cervical cancer (36)
Clinical research (61541)
Collaboration (1530)
Company closure (4)
Compensation (1172)
Complete response letters (77)
COVID-19 (2764)
CRISPR (92)
C-suite (817)
Cystic fibrosis (144)
Data (6009)
Decentralized trials (2)
Denatured (34)
Depression (151)
Diabetes (499)
Diagnostics (5792)
Digital health (39)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (227)
Drug pricing (221)
Drug shortages (33)
Duchenne muscular dystrophy (242)
Earnings (70029)
Editorial (67)
Employer branding (20)
Employer resources (142)
Events (96709)
Executive appointments (914)
FDA (19280)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (20)
Funding (1313)
Gene editing (200)
Generative AI (44)
Gene therapy (622)
GLP-1 (1083)
Government (4447)
Grass and pollen (8)
Guidances (380)
Healthcare (15674)
HIV (65)
Huntington's disease (50)
IgA nephropathy (87)
Immunology and inflammation (296)
Immuno-oncology (63)
Indications (109)
Infectious disease (3037)
Inflammatory bowel disease (192)
Inflation Reduction Act (14)
Influenza (114)
Intellectual property (242)
Interviews (455)
IPO (14703)
IRA (58)
Job creations (3215)
Job search strategy (1678)
JPM (67)
Kidney cancer (17)
Labor market (84)
Layoffs (619)
Leadership (41)
Legal (7234)
Liver cancer (91)
Longevity (13)
Lung cancer (631)
Lymphoma (366)
Machine learning (41)
Management (52)
Manufacturing (756)
MASH (170)
Medical device (11970)
Medtech (12018)
Mergers & acquisitions (15512)
Metabolic disorders (1350)
Multiple sclerosis (154)
NASH (22)
Neurodegenerative disease (339)
Neuropsychiatric disorders (99)
Neuroscience (2991)
Neurotech (1)
NextGen: Class of 2026 (5214)
Non-profit (3403)
Now hiring (32)
Obesity (672)
Opinion (287)
Ovarian cancer (155)
Pain (194)
Pancreatic cancer (227)
Parkinson's disease (284)
Partnered (26)
Patents (490)
Patient recruitment (474)
Peanut (55)
People (45769)
Pharmaceutical (35)
Pharmacy benefit managers (32)
Phase 1 (18315)
Phase 2 (26734)
Phase 3 (21716)
Pipeline (5223)
Policy (339)
Postmarket research (2379)
Preclinical (7578)
Press Release (37)
Prostate cancer (247)
Psychedelics (58)
Radiopharmaceuticals (261)
Rare diseases (907)
Real estate (4449)
Recruiting (65)
Regulatory (23700)
Reports (42)
Research institute (2164)
Resumes & cover letters (405)
Rett syndrome (27)
RNA editing (16)
RSV (77)
Schizophrenia (153)
Series A (220)
Series B (179)
Service/supplier (9)
Sickle cell disease (97)
Special edition (26)
Spinal muscular atrophy (143)
Sponsored (47)
Startups (2865)
State (1)
Stomach cancer (21)
Supply chain (106)
Tariffs (101)
The Weekly (111)
Vaccines (1115)
Venture capital (97)
Weight loss (471)
Women's health (77)
Worklife (22)
Date
Today (142)
Last 7 days (553)
Last 30 days (2268)
Last 365 days (28958)
2026 (3825)
2025 (29097)
2024 (32365)
2023 (36362)
2022 (46520)
2021 (50205)
2020 (47191)
2019 (38127)
2018 (28867)
2017 (28814)
2016 (27345)
2015 (30614)
2014 (24111)
2013 (19571)
2012 (21040)
2011 (21510)
2010 (19456)
Location
Africa (697)
Alabama (74)
Alaska (6)
Arizona (245)
Arkansas (10)
Asia (33704)
Australia (5882)
California (10798)
Canada (2672)
China (962)
Colorado (429)
Connecticut (471)
Delaware (312)
Europe (82033)
Florida (1614)
Georgia (331)
Hawaii (4)
Idaho (42)
Illinois (781)
India (57)
Indiana (454)
Iowa (22)
Japan (418)
Kansas (107)
Kentucky (27)
Louisiana (19)
Maine (74)
Maryland (1326)
Massachusetts (7774)
Michigan (281)
Minnesota (578)
Mississippi (5)
Missouri (123)
Montana (12)
Nebraska (22)
Nevada (113)
New Hampshire (63)
New Jersey (2901)
New Mexico (16)
New York (2809)
North Carolina (1400)
North Dakota (7)
Northern California (5350)
Ohio (287)
Oklahoma (15)
Oregon (34)
Pennsylvania (2083)
Puerto Rico (19)
Rhode Island (32)
South America (1057)
South Carolina (65)
South Dakota (1)
Southern California (4213)
Tennessee (157)
Texas (1604)
United States (37787)
Utah (293)
Virginia (252)
Washington D.C. (75)
Washington State (870)
West Virginia (4)
Wisconsin (113)
Wyoming (1)
588,733 Results for "kedrion s p a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Advanced Infusion Care (AIC) Now Offers Kedrion Biopharma’s YIMMUGO® (Immune Globulin Intravenous Human-Dira, 10% Liquid)
October 21, 2025
·
2 min read
Press Releases
Kedrion Biopharma Receives FDA Approval for QIVIGY® (Immune Globulin 10% IV) for treatment of Primary Humoral Immunodeficiency in Adults and confirms its plan to increase investments in the U.S. throughout its global operations.
September 30, 2025
·
11 min read
Press Releases
Kedrion receives FDA Orphan Drug Designation for investigational plasma-derived treatment for Congenital Aceruloplasminemia
August 7, 2025
·
4 min read
FDA
Kedrion Selected by Biotest to Distribute its Immunoglobulin Yimmugo® in the U.S. Following Recent FDA Approval
Kedrion Biopharma Inc. announced that it has established the framework for a long-term agreement with Biotest AG for the full commercialization and distribution of the immunoglobulin therapy Yimmugo® in the U.S., following its Biologic License Application approval by the U.S. Food and Drug Administration on June 13, 2024.
July 1, 2024
·
5 min read
Press Releases
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
January 29, 2026
·
2 min read
Press Releases
Kedrion Biopharma Receives Orphan Drug Designation for COAGADEX® for Acquired Factor X Deficiency (aFXD) and Starts Clinical Trial to Evaluate Efficacy and Safety
July 30, 2025
·
4 min read
Press Releases
Kedrion Expands Ryplazim Distribution Network for PLGD-1 Patients
March 24, 2025
·
4 min read
Pharm Country
Kedrion Announces Rare Disease Medicine RYPLAZIM® Now Available in US
Kedrion Biopharma Inc. announced today that plasminogen deficiency type 1 (PLGD-1) patients in the U.S. now have access to RYPLAZIM® (plasminogen, human-tvmh).
April 29, 2024
·
5 min read
Press Releases
Kedrion Biopharma closes 2024 with a growth of +10% and unveils its new identity
April 14, 2025
·
6 min read
Press Releases
Indivior Announces Inclusion in the S&P SmallCap 600® Index
December 23, 2025
·
1 min read
1 of 58,874
Next
